Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Smita S Joshi

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 2019
Clinical Assessment of 5-Fluorouracil/Leucovorin, Nab-Paclitaxel, and Irinotecan (FOLFIRABRAX) in Untreated Patients with Gastrointestinal Cancer Using <i>UGT1A1</i> Genotype-Guided DosingSmita S Joshi, Daniel V T Catenacci, Theodore G Karrison, et al.
Journal of the National Cancer Institute|September 12, 2023
Clinical and molecular characteristics of early-onset vs average-onset esophagogastric cancerMelissa A Lumish, Henry Walch, Steven B Maron, et al.
The Lancet. Oncology|September 4, 2023
First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: a single-arm, single-centre, phase 2 trialSamuel L Cytryn, Ryan H Moy, Darren Cowzer, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 2019
Clinical Assessment of 5-Fluorouracil/Leucovorin, Nab-Paclitaxel, and Irinotecan (FOLFIRABRAX) in Untreated Patients with Gastrointestinal Cancer Using <i>UGT1A1</i> Genotype-Guided DosingSmita S Joshi, Daniel V T Catenacci, Theodore G Karrison, et al.
Journal of the National Cancer Institute|September 12, 2023
Clinical and molecular characteristics of early-onset vs average-onset esophagogastric cancerMelissa A Lumish, Henry Walch, Steven B Maron, et al.
The Lancet. Oncology|September 4, 2023
First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: a single-arm, single-centre, phase 2 trialSamuel L Cytryn, Ryan H Moy, Darren Cowzer, et al.
Pageof 2